4DMedical (ASX:4DX) Valuation Check After Half Year Results And CT:VQ Growth Opportunity

Simply Wall St.

Yesterday

4DMedical (ASX:4DX) is back in focus after its half-year results, where the company reported an improved adjusted net loss, a solid cash position, and highlighted its recently approved CT:VQ product. ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2614813961"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2614813961\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2614813961?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/9551730-choice2-main-header/1585186975683","is_english":true,"pubTime":"2026-02-28 14:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2614813961","market":"us","top_or_hot":-1,"title":"4DMedical (ASX:4DX) Valuation Check After Half Year Results And CT:VQ Growth Opportunity","media":"Simply Wall St.","content":"<div>\n<p>4DMedical (ASX:4DX) is back in focus after its half-year results, where the company reported an improved adjusted net loss, a solid cash position, and highlighted its recently approved CT:VQ product. ...</p>\n\n<a href=\"https://simplywall.st/stocks/au/healthcare/asx-4dx/4dmedical-shares/news/4dmedical-asx4dx-valuation-check-after-half-year-results-and\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>4DMedical (ASX:4DX) Valuation Check After Half Year Results And CT:VQ Growth Opportunity</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n4DMedical (ASX:4DX) Valuation Check After Half Year Results And CT:VQ Growth Opportunity\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-28 14:28 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/au/healthcare/asx-4dx/4dmedical-shares/news/4dmedical-asx4dx-valuation-check-after-half-year-results-and><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>4DMedical (ASX:4DX) is back in focus after its half-year results, where the company reported an improved adjusted net loss, a solid cash position, and highlighted its recently approved CT:VQ product. ...</p>\n\n<a href=\"https://simplywall.st/stocks/au/healthcare/asx-4dx/4dmedical-shares/news/4dmedical-asx4dx-valuation-check-after-half-year-results-and\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"4DX.AU","symbol_name":"4DMEDICAL LTD","start_time":0,"source_url":"https://simplywall.st/stocks/au/healthcare/asx-4dx/4dmedical-shares/news/4dmedical-asx4dx-valuation-check-after-half-year-results-and","article_id":"2614813961","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/9551730-choice2-main-header/1585186975683"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/healthcare/asx-4dx/4dmedical-shares/news/4dmedical-asx4dx-valuation-check-after-half-year-results-and","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2614813961","pubTimestamp":1772260090,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"4DMedical (ASX:4DX) is back in focus after its half-year results, where the company reported an improved adjusted net loss, a solid cash position, and highlighted its recently approved CT:VQ product.\nSee our latest analysis for 4DMedical.\nAt a latest share price of A$4.00, 4DMedical has seen a 12.68% 1 month share price return and a 133.92% 3 month share price return, while its 1 year total shareholder return is very large. This suggests momentum has been building around the CT:VQ rollout and...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"4DX.AU":"4DMEDICAL LTD","BK7094":"医疗保健技术"},"translate_title":"4DMedical(ASX：4DX)半年业绩和CT后的估值检查：VQ增长机会","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"4DX.AU":1.5},"content_text":"4DMedical (ASX:4DX) is back in focus after its half-year results, where the company reported an improved adjusted net loss, a solid cash position, and highlighted its recently approved CT:VQ product. See our latest analysis for 4DMedical. At a latest share price of A$4.00, 4DMedical has seen a 12.68% 1 month share price return and a 133.92% 3 month share price return, while its 1 year total shareholder return is very large. This suggests momentum has been building around the CT:VQ rollout and recent half year results as investors reassess both growth potential and risk. If this kind of move in medical imaging gets you thinking more broadly about opportunities, take a look at our screener of 10 healthcare AI stocks as a starting list of ideas to research next. With 4DMedical now trading above the latest analyst price target and carrying a very large 1 year return, the key question is whether recent excitement leaves the stock undervalued or whether the market is already pricing in future growth. AdvertisementMost Popular Narrative: 64% Undervalued According to the most followed narrative, 4DMedical's fair value of A$11.11 sits well above the latest A$4.00 share price, which puts a spotlight on how ambitious that view really is.  4DMedical is the first non invasive, contrast free imaging technology for lung scanning. The new CT:VQ lung scanner is the first technology of its kind and is rapidly being adopted by clinics and big name KOL's in America. 4DMedical's goals for 2026 are to rapidly scale and expand across major AMC's, building more credibility and reputation among other clinics to help expand their technology. Partnership with Philips promised a $10 Million USD minimum order commitment contract over the next 2 years starting December 2025 (over 2026 and 2027). Philips has added 4DMedical's CT:VQ technology as an official product on their catalog in North America. Backing by PME (Pro Medicus) with a $10 Million AUD strategic investment, a hybrid type of debt / equity investment in 4DX. An interest rate of 12.5% p.a that 4DX (4DMedical) needs to repay PME (ProMedicus) with a maturity of 2 years.  Read the complete narrative. Want to see what sits behind that A$11.11 fair value? According to ethanwong, the story leans heavily on rapid revenue expansion, very high margins, and a rich future earnings multiple. Curious how those ingredients are combined to justify such a big gap to today's price? The full narrative lays out the numbers and timing in detail. Result: Fair Value of A$11.11 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, this story still faces real pressure points, including 4DMedical's current A$30.07m net loss and the risk that expected contract demand or adoption timelines could slip. Find out about the key risks to this 4DMedical narrative. Another Way To Look At Valuation That A$11.11 fair value from the user narrative sits beside a very different signal from the market. On a P/B of 35.6x versus an Australian peer average of 20.1x and a global industry average of 2.4x, 4DMedical already carries a rich price tag. Does that premium reflect future potential, or does it add valuation risk? See what the numbers say about this price — find out in our valuation breakdown. ASX:4DX P/B Ratio as at Feb 2026Next Steps With such a bullish narrative set against rich multiples and real execution risks, do you feel the optimism or the caution more strongly right now? If you want to move past headlines and weigh both sides for yourself, take a moment to review the 1 key reward and 4 important warning signs so you can judge how the trade off between potential and risk stacks up for you. Looking for more investment ideas? If you want to keep sharpening your edge beyond 4DMedical, you owe it to yourself to scan a few more ideas before making your next move.  Target higher quality potential by reviewing our screener of 8 high quality undervalued stocks that pair strong fundamentals with prices that may not fully reflect them yet. Prioritise resilience by checking companies in our 8 resilient stocks with low risk scores that focus on steadier balance sheets and lower overall risk profiles. Hunt for future standouts by scanning our screener containing 12 high quality undiscovered gems where smaller, less followed names might offer fresh ideas for your watchlist.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}